VIP (Vasoactive Intestinal Peptide) vs Semaglutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
VIP (Vasoactive Intestinal Peptide)
VIP is a 28-amino acid neuropeptide with wide-ranging effects throughout the body. It acts as a neurotransmitter, neuromodulator, and immune regulator with particular importance in gut and lung function.
Full details →Semaglutide
Semaglutide is a GLP-1 receptor agonist that has revolutionized weight management and diabetes treatment. FDA-approved as Ozempic (diabetes), Wegovy (weight loss), and Rybelsus (oral form), it has become one of the most prescribed peptides worldwide.
Full details →Side-by-Side Comparison
| Aspect | VIP (Vasoactive Intestinal Peptide) | Semaglutide |
|---|---|---|
| Mechanism | Binds to VPAC1 and VPAC2 receptors to modulate immune responses, regulate circadian rhythms, promote vasodilation, and support barrier function in gut and lungs. Has potent anti-inflammatory effects. | Mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through hypothalamic signaling. The result is significant reduction in food intake and improved glycemic control. |
| Typical Dosage | Intranasal: 50-200mcg 1-3 times daily for chronic inflammatory conditions. Some protocols use subcutaneous administration. Dosing varies by condition. | Wegovy (weight loss): Start at 0.25mg weekly, titrate up to 2.4mg weekly over 16-20 weeks. Ozempic (diabetes): 0.25mg to 1mg weekly. Research protocols vary. |
| Administration | Intranasal is most common for inflammatory conditions. Subcutaneous injection also used. Must be stored cold and protected from light. | Subcutaneous injection once weekly, typically in abdomen, thigh, or upper arm. Rybelsus is taken orally on empty stomach. Dose titration is essential to minimize GI side effects. |
| Side Effects | May cause nasal irritation, flushing, headache, or temporary diarrhea. Generally well-tolerated at standard doses. | Common: nausea, vomiting, diarrhea, constipation, abdominal pain. These typically decrease over time. May cause injection site reactions. |
| Best For |
What They Have in Common
Both VIP (Vasoactive Intestinal Peptide) and Semaglutide are commonly used for: